FDA authorizes new monkeypox point-of-care test, updates COVID-19 medical device shortages
The Food and Drug Administration Friday authorized for emergency use a molecular test to detect mpox (formerly known as monkeypox) at the point of care in lesion swab specimens from individuals whose health care provider suspects they have the virus.
In other news, FDA last week updated its list of medical device shortages and discontinued medical devices during the COVID-19 public health emergency.
Related News Articles
Headline
As summer Pride parades and other large gatherings approach, Americans at high risk for mpox (monkeypox) exposure should ensure they are fully vaccinated with…
Headline
The Food and Drug Administration Friday authorized for emergency use a real-time polymerase chain reaction test to detect mpox (formerly known as…
Headline
In a study of men under age 50 who were eligible to receive the JYNNEOS vaccine to prevent monkeypox (mpox) during the U.S. outbreak this year, unvaccinated…
Headline
The World Health Organization today recommended a new name for monkeypox that is intended to mitigate a rise in related racist and stigmatizing language…
Headline
The Department of Health and Human Services today renewed the nation’s monkeypox public health emergency declaration for another 90 days. When the PHE was…
Headline
As the monkeypox outbreak slows in the U.S., a new report from the Centers for Disease Control and Prevention highlights devastating outcomes of monkeypox for…